Loading...
Market
Will the Stryker-Inari acquisition receive regulatory approval by March 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Announcements by regulatory bodies or official statements from Stryker or Inari Medical
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80/Share, Focusing on VTE Treatments
Jan 6, 2025, 09:09 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. This acquisition will allow Stryker to expand its offerings into the high-growth peripheral vascular segment, focusing on venous thromboembolism (VTE) treatments. Inari's innovative product portfolio, which includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism, complements Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
No • 50%
Yes • 50%
Modified Terms • 25%
Completed • 25%
Delayed • 25%
Cancelled • 25%
Neutral • 25%
Positive • 25%
Negative • 25%
Unchanged • 25%
Full Integration • 25%
Discontinued Products • 25%
Independent Operation • 25%
Partial Integration • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
